Search Results - "Kappeler, D."
-
1
Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis
Published in Journal of cystic fibrosis (01-03-2020)“…AbstractBackgroundPOL6014 is a novel, orally inhaled neutrophil elastase (NE) inhibitor in development for cystic fibrosis (CF). MethodsTwo studies, one in…”
Get full text
Journal Article -
2
WS01.4 A randomised, double-blind, placebo-controlled, parallel-group, dose-escalation study of inhaled single doses of POL6014, a potent and selective reversible inhibitor of human neutrophil elastase (NE), in cystic fibrosis (CF) patients
Published in Journal of cystic fibrosis (01-06-2017)Get full text
Journal Article -
3
61 A randomised, double-blind, placebo-controlled, parallel-group, dose-escalation phase I study in healthy volunteers (HV) of inhaled single doses (SD) of POL6014, a potent and selective reversible inhibitor of human neutrophil elastase
Published in Journal of cystic fibrosis (01-06-2017)Get full text
Journal Article -
4
-
5
Allergen-Induced Asthmatic Responses Modified by a GATA3-Specific DNAzyme
Published in The New England journal of medicine (21-05-2015)“…GATA3 is thought to be a critical checkpoint in allergic diathesis. In this study, a synthetic DNAzyme that catalyzes the inactivation of GATA3 when…”
Get full text
Journal Article -
6
Macroprolactinaemia: the major unknown in the differential diagnosis of hyperprolactinaemia
Published in Swiss medical weekly (10-03-2001)Get full text
Journal Article -
7
Ensuring Patient Safety and Data Integrity in Clinical Trials for the Treatment of Bronchiolitis Obliterans Syndrome (BOS) during the COVID-19 Pandemic
Published in The Journal of heart and lung transplantation (01-04-2021)“…The current COVID-19 pandemic has posed challenges to the conduct of clinical trials. BOSTON-1 and BOSTON-2 are two ongoing phase III, prospective,…”
Get full text
Journal Article -
8
Liposomal Cyclosporine A (L-CsA) via Inhalation to Treat Bronchiolitis Obliterans Syndrome: Novel Formulation and Drug-Specific Delivery System Improves Tolerability
Published in The Journal of heart and lung transplantation (01-04-2019)“…Bronchiolitis obliterans syndrome (BOS) is the major obstacle to long-term benefit after lung transplantation. There is no therapy with demonstrated benefit…”
Get full text
Journal Article -
9
A40 CYSTIC FIBROSIS AND NON-CYSTIC FIBROSIS BRONCHIECTASIS: Characteristics Of The T-326 Inhaler Important For Effective Inhalation Treatment With Ciprofloxacin Dry Powder For Inhalation In Patients With Non-Cystic Fibrosis Bronchiectasis
Published in American journal of respiratory and critical care medicine (01-01-2017)“…In order to ensure reliable and reproducible drug delivery to the lung, all patients (including those with reduced lung function) need to have an inspiratory…”
Get full text
Journal Article -
10
-
11
Macroprolactinaemia, the major unknown in the differential diagnosis of hyperprolactinaemia
Published in Swiss medical weekly (10-03-2001)“…We report on 10 cases of macroprolactinaemia and discuss recent evidence that many patients with hyperprolactinaemia (8-26%, depending on the population…”
Get full text
Journal Article -
12
-
13
Les Réserves dans les Traités Internationaux
Published in The American Journal of Comparative Law (01-10-1958)Get full text
Book Review Journal Article